COMPANY
Alume Biosciences, Inc.
Funding and NIH signals
- SEC Form D raise Raised $2.16M (Form D filed Apr 6, 2026; amended May 8, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001782348-26-000005 (Apr 6, 2026)
Evidence (2 events)
- Apr 6, 2026 · SEC Form D 0001782348-26-000005
Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 110000; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-05-08; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 2160000; Federal exemptions: 06b - Oct 31, 2025 · SEC Form D 0001782348-25-000003
Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D; Filing date: 2025-10-31; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 3055500; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2025-11-12; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 3611116; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2025-12-31; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 5316105; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-01-30; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 5967305; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-02-19; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 6853305; Federal exemptions: 06b
- Apr 6, 2026 · SEC Form D 0001782348-26-000005
Timeline
- Trial start Phase 2: A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery source ↗
- Trial start Phase 2/Phase 3: Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery source ↗
- Trial start Phase 3: Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery source ↗
- Trial start Phase 1/Phase 2: Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06662097 | A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery | Phase 2 | Completed | Oct 16, 2024 | Jan 2, 2026 (actual) |
| NCT05377554 | Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery | Phase 3 | Completed | Apr 29, 2022 | Oct 27, 2025 (actual) |
| NCT06227585 | Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery | Phase 2/Phase 3 | Completed | Nov 29, 2023 | Oct 24, 2025 (actual) |
| NCT04420689 | Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery | Phase 1/Phase 2 | Completed | Jun 18, 2020 | Jun 25, 2021 (actual) |
NIH awards 7
- NIH award 5R44CA275546-02 FY2024: $865,615 awarded for that fiscal year; activity R44 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Development of ALM-488 for nerve and source ↗
- NIH award 1R44CA275546-01A1 FY2023: $937,219 awarded for that fiscal year; activity R44 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Development of ALM-488 for nerve an source ↗
- NIH award 5SB1NS127647-02 FY2023: $1,690,637 awarded for that fiscal year; activity SB1 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Commercialization of ALM-488 for Hi source ↗
- NIH award 1SB1NS127647-01 FY2022: $1,670,941 awarded for that fiscal year; activity SB1 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Commercialization of ALM-488 for Hi source ↗
- NIH award 5R44NS108827-03 FY2021: $1,177,711 awarded for that fiscal year; activity R44 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Development of Fluorescent Probes f source ↗
- NIH award 2R44NS108827-02 FY2020: $1,347,839 awarded for that fiscal year; activity R44 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Development of Fluorescent Probes f source ↗
- NIH award 1R43NS108827-01A1 FY2019: $299,912 awarded for that fiscal year; activity R43 (SBIR); PI WHITNEY, MICHAEL A; recipient as written: ALUME BIOSCIENCES, INC., San Diego, CA. Development of Fluorescent Probes f source ↗